Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases

Table of Contents

In This Issue

  • In This Issue
    In This Issue
    Cancer Discov February 1 2018 8 (2) 127-129; DOI:10.1158/2159-8290.CD-ITI8-2

In the Spotlight

  • In the Spotlight
    ERK Inhibition: A New Front in the War against MAPK Pathway–Driven Cancers?
    Inna Smalley and Keiran S.M. Smalley
    Cancer Discov February 1 2018 8 (2) 140-142; DOI:10.1158/2159-8290.CD-17-1355

  • In the Spotlight
    A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?
    Justin M. Balko and Jeffrey A. Sosman
    Cancer Discov February 1 2018 8 (2) 143-145; DOI:10.1158/2159-8290.CD-17-1356

  • In the Spotlight
    What's the FOX Got to Do with the KITten? Regulating the Lineage-Specific Transcriptional Landscape in GIST
    Donna M. Lee and Anette Duensing
    Cancer Discov February 1 2018 8 (2) 146-149; DOI:10.1158/2159-8290.CD-17-1370

Review

  • Review | AuthorChoice
    The Expanding World of N-MYC–Driven Tumors
    David S. Rickman, Johannes H. Schulte and Martin Eilers
    Cancer Discov February 1 2018 8 (2) 150-163; DOI:10.1158/2159-8290.CD-17-0273

Research Briefs

  • Research Briefs | AuthorChoice
    Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
    John H. Strickler, Jonathan M. Loree, Leanne G. Ahronian, Aparna R. Parikh, Donna Niedzwiecki, Allan Andresson Lima Pereira, Matthew McKinney, W. Michael Korn, Chloe E. Atreya, Kimberly C. Banks, Rebecca J. Nagy, Funda Meric-Bernstam, Richard B. Lanman, AmirAli Talasaz, Igor F. Tsigelny, Ryan B. Corcoran and Scott Kopetz
    Cancer Discov February 1 2018 8 (2) 164-173; DOI:10.1158/2159-8290.CD-17-1009

    cfDNA profiling has high concordance with direct tumor sequencing in 1,397 patients with advanced colorectal cancer and uncovers EGFR ECD mutations that may drive resistance to anti-EGFR antibodies.

  • Research Briefs | AuthorChoice
    Accelerating Discovery of Functional Mutant Alleles in Cancer
    Matthew T. Chang, Tripti Shrestha Bhattarai, Alison M. Schram, Craig M. Bielski, Mark T.A. Donoghue, Philip Jonsson, Debyani Chakravarty, Sarah Phillips, Cyriac Kandoth, Alexander Penson, Alexander Gorelick, Tambudzai Shamu, Swati Patel, Christopher Harris, JianJiong Gao, Selcuk Onur Sumer, Ritika Kundra, Pedram Razavi, Bob T. Li, Dalicia N. Reales, Nicholas D. Socci, Gowtham Jayakumaran, Ahmet Zehir, Ryma Benayed, Maria E. Arcila, Sarat Chandarlapaty, Marc Ladanyi, Nikolaus Schultz, José Baselga, Michael F. Berger, Neal Rosen, David B. Solit, David M. Hyman and Barry S. Taylor
    Cancer Discov February 1 2018 8 (2) 174-183; DOI:10.1158/2159-8290.CD-17-0321

    Analysis of somatic mutational data in large patient cohorts uncovered rare hotspots that may accelerate the discovery of rare driver mutations in cancer and guide selection of targeted therapies.

Research Articles

  • Research Articles | AuthorChoice
    First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
    Ryan J. Sullivan, Jeffrey R. Infante, Filip Janku, Deborah Jean Lee Wong, Jeffrey A. Sosman, Vicki Keedy, Manish R. Patel, Geoffrey I. Shapiro, James W. Mier, Anthony W. Tolcher, Andrea Wang-Gillam, Mario Sznol, Keith Flaherty, Elizabeth Buchbinder, Richard D. Carvajal, Anna M. Varghese, Mario E. Lacouture, Antoni Ribas, Sapna P. Patel, Gary A. DeCrescenzo, Caroline M. Emery, Anna L. Groover, Saurabh Saha, Mary Varterasian, Dean J. Welsch, David M. Hyman and Bob T. Li
    Cancer Discov February 1 2018 8 (2) 184-195; DOI:10.1158/2159-8290.CD-17-1119

    The ERK inhibitor ulixertinib is well tolerated and achieved partial responses in patients with NRAS-, BRAFV600-, and non-V600 BRAF-mutant advanced solid tumors in a phase I clinical trial.

  • Research Articles
    Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
    Russell W. Jenkins, Amir R. Aref, Patrick H. Lizotte, Elena Ivanova, Susanna Stinson, Chensheng W. Zhou, Michaela Bowden, Jiehui Deng, Hongye Liu, Diana Miao, Meng Xiao He, William Walker, Gao Zhang, Tian Tian, Chaoran Cheng, Zhi Wei, Sangeetha Palakurthi, Mark Bittinger, Hans Vitzthum, Jong Wook Kim, Ashley Merlino, Max Quinn, Chandrasekar Venkataramani, Joshua A. Kaplan, Andrew Portell, Prafulla C. Gokhale, Bart Phillips, Alicia Smart, Asaf Rotem, Robert E. Jones, Lauren Keogh, Maria Anguiano, Lance Stapleton, Zhiheng Jia, Michal Barzily-Rokni, Israel Cañadas, Tran C. Thai, Marc R. Hammond, Raven Vlahos, Eric S. Wang, Hua Zhang, Shuai Li, Glenn J. Hanna, Wei Huang, Mai P. Hoang, Adriano Piris, Jean-Pierre Eliane, Anat O. Stemmer-Rachamimov, Lisa Cameron, Mei-Ju Su, Parin Shah, Benjamin Izar, Manisha Thakuria, Nicole R. LeBoeuf, Guilherme Rabinowits, Viswanath Gunda, Sareh Parangi, James M. Cleary, Brian C. Miller, Shunsuke Kitajima, Rohit Thummalapalli, Benchun Miao, Thanh U. Barbie, Vivek Sivathanu, Joshua Wong, William G. Richards, Raphael Bueno, Charles H. Yoon, Juan Miret, Meenhard Herlyn, Levi A. Garraway, Eliezer M. Van Allen, Gordon J. Freeman, Paul T. Kirschmeier, Jochen H. Lorch, Patrick A. Ott, F. Stephen Hodi, Keith T. Flaherty, Roger D. Kamm, Genevieve M. Boland, Kwok-Kin Wong, David Dornan, Cloud Peter Paweletz and David A. Barbie
    Cancer Discov February 1 2018 8 (2) 196-215; DOI:10.1158/2159-8290.CD-17-0833

    Mouse- and patient-derived organotypic tumor spheroids model the tumor-immune microenvironment to predict response and resistance to anti–PD-1 and evaluate potential combination therapies.

  • Research Articles
    CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
    Jiehui Deng, Eric S. Wang, Russell W. Jenkins, Shuai Li, Ruben Dries, Kathleen Yates, Sandeep Chhabra, Wei Huang, Hongye Liu, Amir R. Aref, Elena Ivanova, Cloud P. Paweletz, Michaela Bowden, Chensheng W. Zhou, Grit S. Herter-Sprie, Jessica A. Sorrentino, John E. Bisi, Patrick H. Lizotte, Ashley A. Merlino, Max M. Quinn, Lauren E. Bufe, Annan Yang, Yanxi Zhang, Hua Zhang, Peng Gao, Ting Chen, Megan E. Cavanaugh, Amanda J. Rode, Eric Haines, Patrick J. Roberts, Jay C. Strum, William G. Richards, Jochen H. Lorch, Sareh Parangi, Viswanath Gunda, Genevieve M. Boland, Raphael Bueno, Sangeetha Palakurthi, Gordon J. Freeman, Jerome Ritz, W. Nicholas Haining, Norman E. Sharpless, Haribabu Arthanari, Geoffrey I. Shapiro, David A. Barbie, Nathanael S. Gray and Kwok-Kin Wong
    Cancer Discov February 1 2018 8 (2) 216-233; DOI:10.1158/2159-8290.CD-17-0915

    CDK4/6 inhibitors derepress NFAT to promote IL2 secretion, enhance T-cell activation and tumor infiltration, and cooperate with anti–PD-1 antibodies to boost antitumor immunity in vivo.

  • Research Articles
    FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor
    Leili Ran, Yuedan Chen, Jessica Sher, Elissa W.P. Wong, Devan Murphy, Jenny Q. Zhang, Dan Li, Kemal Deniz, Inna Sirota, Zhen Cao, Shangqian Wang, Youxin Guan, Shipra Shukla, Katie Yang Li, Alan Chramiec, Yuanyuan Xie, Deyou Zheng, Richard P. Koche, Cristina R. Antonescu, Yu Chen and Ping Chi
    Cancer Discov February 1 2018 8 (2) 234-251; DOI:10.1158/2159-8290.CD-17-0468

    Gastrointestinal stromal tumors exhibit a transcriptional dependence on FOXF1, which binds enhancers to promote expression of genes, including ETV1 and KIT, required for tumor growth.

News in Brief

  • News in Brief
    People
    Cancer Discov February 1 2018 8 (2) 130-130; DOI:10.1158/2159-8290.CD-NB2017-173

  • News in Brief
    FDA Approves Trastuzumab Biosimilar
    Cancer Discov February 1 2018 8 (2) 130-130; DOI:10.1158/2159-8290.CD-NB2017-183

  • News in Brief
    Anti–PD-1 Therapy OK for Most with HIV
    Cancer Discov February 1 2018 8 (2) 130-131; DOI:10.1158/2159-8290.CD-NB2017-174

  • News in Brief
    CTCs May Predict Breast Cancer Recurrence
    Cancer Discov February 1 2018 8 (2) 131-131; DOI:10.1158/2159-8290.CD-NB2017-178

  • News in Brief
    Value in Using CAR T Cells for DLBCL
    Cancer Discov February 1 2018 8 (2) 131-132; DOI:10.1158/2159-8290.CD-NB2017-179

  • News in Brief
    Role for Immune Therapy in Advanced Breast Cancer
    Cancer Discov February 1 2018 8 (2) 132-133; DOI:10.1158/2159-8290.CD-NB2017-176

  • News in Brief
    Rapid Responses to Avapritinib (BLU-285) in Mastocytosis
    Cancer Discov February 1 2018 8 (2) 133-133; DOI:10.1158/2159-8290.CD-NB2017-177

  • News in Brief
    Noted
    Cancer Discov February 1 2018 8 (2) 133-133; DOI:10.1158/2159-8290.CD-NB2017-172

  • News in Brief
    Mogamulizumab Tops Standard of Care for CTCL
    Cancer Discov February 1 2018 8 (2) OF1-OF1; DOI:10.1158/2159-8290.CD-NB2018-001

  • News in Brief
    CAR T-cell Therapy Impresses in Multiple Myeloma
    Cancer Discov February 1 2018 8 (2) OF2-OF2; DOI:10.1158/2159-8290.CD-NB2017-181

  • News in Brief
    Talazoparib Bests Chemo for Breast Cancer
    Cancer Discov February 1 2018 8 (2) OF3-OF3; DOI:10.1158/2159-8290.CD-NB2017-180

  • News in Brief
    Fusobacterium Travels with Colorectal Cancer Cells
    Cancer Discov February 1 2018 8 (2) OF4-OF4; DOI:10.1158/2159-8290.CD-NB2017-171

  • News in Brief
    Ribociclib Extends Survival in HR+ Breast Cancer
    Cancer Discov February 1 2018 8 (2) OF5-OF5; DOI:10.1158/2159-8290.CD-NB2017-175

News in Depth

  • News in Depth
    Gut Bacteria Shape Therapeutic Response
    Cancer Discov February 1 2018 8 (2) 134-134; DOI:10.1158/2159-8290.CD-ND2018-001

Research Watch

  • Clinical Trials

    • Research Watch
      HIF2α Antagonism Has Antitumor Activity in Advanced ccRCC
      Cancer Discov February 1 2018 8 (2) OF6-OF6; DOI:10.1158/2159-8290.CD-RW2018-007

    • Research Watch
      PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer
      Cancer Discov February 1 2018 8 (2) 136-136; DOI:10.1158/2159-8290.CD-RW2017-238

  • Drug Evaluation

    • Research Watch
      The Alcohol-Abuse Drug Disulfiram Targets NPL4 to Exert Antitumor Effects
      Cancer Discov February 1 2018 8 (2) OF7-OF7; DOI:10.1158/2159-8290.CD-RW2017-235

  • Epigenetics

    • Research Watch
      Ependymoma Superenhancer Profiling Reveals Potential Therapeutic Targets
      Cancer Discov February 1 2018 8 (2) OF8-OF8; DOI:10.1158/2159-8290.CD-RW2018-006

    • Research Watch
      KAT2A Is a α-KGDH–Dependent Histone Succinyltransferase
      Cancer Discov February 1 2018 8 (2) 138-138; DOI:10.1158/2159-8290.CD-RW2017-234

  • Gene Expression

    • Research Watch
      YY1 Facilitates Enhancer–Promoter Contacts to Promote Gene Expression
      Cancer Discov February 1 2018 8 (2) 135-135; DOI:10.1158/2159-8290.CD-RW2017-233

  • Immunotherapy

    • Research Watch
      Response to Immune Checkpoint Blockade is Influenced by HLA-I Genotype
      Cancer Discov February 1 2018 8 (2) 139-139; DOI:10.1158/2159-8290.CD-RW2017-236

  • Leukemia

    • Research Watch
      R-2HG Targets FTO to Increase m6A Levels and Suppress Tumor Growth
      Cancer Discov February 1 2018 8 (2) 137-137; DOI:10.1158/2159-8290.CD-RW2017-240

  • Liver Cancer

    • Signaling
      mTORC2-Driven Lipid Synthesis Promotes Liver Tumorigenesis
      Cancer Discov February 1 2018 8 (2) OF9-OF9; DOI:10.1158/2159-8290.CD-RW2017-237

  • Metabolism

    • Research Watch
      FGFR3–TACC3 Activates Mitochondrial Respiration via PIN4 Phosphorylation
      Cancer Discov February 1 2018 8 (2) 139-139; DOI:10.1158/2159-8290.CD-RW2018-008

  • Metastasis

    • Research Watch
      Glutaminolysis Drives Lung Cancer Metastasis via the PLAG1–GDH1 Axis
      Cancer Discov February 1 2018 8 (2) 135-135; DOI:10.1158/2159-8290.CD-RW2018-004

    • Research Watch
      Targeting JAG1 Sensitizes Bone Metastases to Chemotherapy
      Cancer Discov February 1 2018 8 (2) 137-137; DOI:10.1158/2159-8290.CD-RW2017-239

  • Myeloproliferative Disease

    • Research Watch
      Myeloproliferative Neoplasms May Be Sensitive to Dual BET/JAK Inhibition
      Cancer Discov February 1 2018 8 (2) OF10-OF10; DOI:10.1158/2159-8290.CD-RW2018-002

  • Pancreatic Cancer

    • Research Watch
      An Adrenergic–Neurotrophin Feedforward Loop Promotes Pancreatic Cancer
      Cancer Discov February 1 2018 8 (2) 138-138; DOI:10.1158/2159-8290.CD-RW2018-003

  • Senescence

    • Research Watch
      Senescence-Associated Chromatin Remodeling Promotes Cancer Stemness
      Cancer Discov February 1 2018 8 (2) 136-136; DOI:10.1158/2159-8290.CD-RW2018-005

  • Structural Biology

    • Research Watch
      Determination of mTORC1 Complex Structures Reveals Regulatory Mechanisms
      Cancer Discov February 1 2018 8 (2) OF11-OF11; DOI:10.1158/2159-8290.CD-RW2018-001

Back to top
PreviousNext
Cancer Discovery: 8 (2)
February 2018
Volume 8, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • In This Issue
  • In the Spotlight
  • Review
  • Research Briefs
  • Research Articles
  • News in Brief
  • News in Depth
  • Research Watch
    • Clinical Trials
    • Drug Evaluation
    • Epigenetics
    • Gene Expression
    • Immunotherapy
    • Leukemia
    • Liver Cancer
    • Metabolism
    • Metastasis
    • Myeloproliferative Disease
    • Pancreatic Cancer
    • Senescence
    • Structural Biology
Advertisement
  • Most Cited
  • Most Read
Loading
  • The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
  • Macrophages Regulate Response to Chemotherapy
  • Core Resistance Mechanisms and Genetic Evolution of Melanoma under BRAF Inhibitor Selection
  • EGFR Mediates RAF Inhibitor Resistance in BRAF-Mutant Colorectal Cancer
  • Novel Mutant-Selective EGFR Inhibitor Overcomes Drug Resistance
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement